Cargando…

L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model

Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Beever, Abrianna, Kachour, Nala, Owens, James, Sasaninia, Kayvan, Kolloli, Afsal, Kumar, Ranjeet, Ramasamy, Santhamani, Sisliyan, Christina, Khamas, Wael, Subbian, Selvakumar, Venketaraman, Vishwanath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263396/
https://www.ncbi.nlm.nih.gov/pubmed/35814213
http://dx.doi.org/10.3389/fphar.2022.879729
_version_ 1784742727010746368
author Beever, Abrianna
Kachour, Nala
Owens, James
Sasaninia, Kayvan
Kolloli, Afsal
Kumar, Ranjeet
Ramasamy, Santhamani
Sisliyan, Christina
Khamas, Wael
Subbian, Selvakumar
Venketaraman, Vishwanath
author_facet Beever, Abrianna
Kachour, Nala
Owens, James
Sasaninia, Kayvan
Kolloli, Afsal
Kumar, Ranjeet
Ramasamy, Santhamani
Sisliyan, Christina
Khamas, Wael
Subbian, Selvakumar
Venketaraman, Vishwanath
author_sort Beever, Abrianna
collection PubMed
description Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb infection and are more susceptible to reactivation of LTBI to active diseases. T2DM cases are known to have glutathione (GSH) deficiency and impaired immune cell function, including the granulomatous response to M. tb infection. We have previously reported that liposomal glutathione (L-GSH) supplementation can restore the immune cell effector responses of T2DM cases. However, the effects of L-GSH supplementation on the bactericidal activities of first-line anti-TB drug rifampicin (RIF) against M. tb infection have yet to be explored. The aim of this study is to elucidate the effects of L-GSH supplementation in conjunction with RIF treatment during an active M. tb infection in a diabetic mouse model. In this study, we evaluated total and reduced levels of GSH, cytokine profiles, malondialdehyde (MDA) levels, M. tb burden, and granulomatous response in the lungs. We show that L-GSH supplementation caused a significant reduction in M. tb burden in the lungs, decreased oxidative stress, and increased the production of IFN-γ, TNF-α, IL-17, IL-10, and TGF-β1compared to the untreated mice. In addition, L-GSH supplementation in conjunction with RIF treatment achieved better control of M. tb infection in the lungs and significantly reduced the levels of oxidative stress compared to treatment with RIF alone. Moreover, L-GSH in conjunction with RIF significantly increased TGF-β1 levels compared to treatment with RIF alone. These findings suggest potential therapeutic benefits of L-GSH supplementation in conjunction with first-line antibiotic therapy against M. tb infection in individuals with T2DM.
format Online
Article
Text
id pubmed-9263396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92633962022-07-09 L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model Beever, Abrianna Kachour, Nala Owens, James Sasaninia, Kayvan Kolloli, Afsal Kumar, Ranjeet Ramasamy, Santhamani Sisliyan, Christina Khamas, Wael Subbian, Selvakumar Venketaraman, Vishwanath Front Pharmacol Pharmacology Both active tuberculosis (TB) and asymptomatic latent Mycobacterium tuberculosis (M. tb) infection (LTBI) cause significant health burdens to humans worldwide. Individuals with immunocompromising health conditions, such as Type 2 Diabetes Mellitus (T2DM), have a weakened ability to control M. tb infection and are more susceptible to reactivation of LTBI to active diseases. T2DM cases are known to have glutathione (GSH) deficiency and impaired immune cell function, including the granulomatous response to M. tb infection. We have previously reported that liposomal glutathione (L-GSH) supplementation can restore the immune cell effector responses of T2DM cases. However, the effects of L-GSH supplementation on the bactericidal activities of first-line anti-TB drug rifampicin (RIF) against M. tb infection have yet to be explored. The aim of this study is to elucidate the effects of L-GSH supplementation in conjunction with RIF treatment during an active M. tb infection in a diabetic mouse model. In this study, we evaluated total and reduced levels of GSH, cytokine profiles, malondialdehyde (MDA) levels, M. tb burden, and granulomatous response in the lungs. We show that L-GSH supplementation caused a significant reduction in M. tb burden in the lungs, decreased oxidative stress, and increased the production of IFN-γ, TNF-α, IL-17, IL-10, and TGF-β1compared to the untreated mice. In addition, L-GSH supplementation in conjunction with RIF treatment achieved better control of M. tb infection in the lungs and significantly reduced the levels of oxidative stress compared to treatment with RIF alone. Moreover, L-GSH in conjunction with RIF significantly increased TGF-β1 levels compared to treatment with RIF alone. These findings suggest potential therapeutic benefits of L-GSH supplementation in conjunction with first-line antibiotic therapy against M. tb infection in individuals with T2DM. Frontiers Media S.A. 2022-06-24 /pmc/articles/PMC9263396/ /pubmed/35814213 http://dx.doi.org/10.3389/fphar.2022.879729 Text en Copyright © 2022 Beever, Kachour, Owens, Sasaninia, Kolloli, Kumar, Ramasamy, Sisliyan, Khamas, Subbian and Venketaraman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Beever, Abrianna
Kachour, Nala
Owens, James
Sasaninia, Kayvan
Kolloli, Afsal
Kumar, Ranjeet
Ramasamy, Santhamani
Sisliyan, Christina
Khamas, Wael
Subbian, Selvakumar
Venketaraman, Vishwanath
L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
title L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
title_full L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
title_fullStr L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
title_full_unstemmed L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
title_short L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
title_sort l-gsh supplementation in conjunction with rifampicin augments the treatment response to mycobacterium tuberculosis in a diabetic mouse model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263396/
https://www.ncbi.nlm.nih.gov/pubmed/35814213
http://dx.doi.org/10.3389/fphar.2022.879729
work_keys_str_mv AT beeverabrianna lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT kachournala lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT owensjames lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT sasaniniakayvan lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT kolloliafsal lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT kumarranjeet lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT ramasamysanthamani lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT sisliyanchristina lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT khamaswael lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT subbianselvakumar lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel
AT venketaramanvishwanath lgshsupplementationinconjunctionwithrifampicinaugmentsthetreatmentresponsetomycobacteriumtuberculosisinadiabeticmousemodel